← Drug database

Klygefa (gefurulimab)

New biologic
Region
🇺🇸 US
Active substance
gefurulimab
Company
Alexion Pharm
Status
Approved
FDA approval
Fri 13 Nov 2026
Designations
New biologic
Application
BLA761488
Official record
www.accessdata.fda.gov

Regulatory milestones

Mon 23 Nov 2026🇪🇺 Expected EC decisionestimate

Klygefa (gefurulimab): expected EC decision

Estimated as CHMP opinion (2026-09-17) + 67 days, the standard Commission decision period. Not an official date. · Alexion Europe · source

Fri 13 Nov 2026🇺🇸 FDA approval

FDA approves Klygefa (gefurulimab), a new medicine

Alexion Pharm; BLA761488; New biologic; solution · source

Thu 17 Sep 2026🇪🇺 CHMP positive opinion

Klygefa (gefurulimab): CHMP positive opinion

Alexion Europe · source

In-depth analysis

Where it stands

Klygefa (gefurulimab), from Alexion Pharm, is recorded as approved in the US. The FDA approval is dated 2026-11-13 under BLA761488. The product is a new biologic supplied as a solution.

In the EU, the same substance is at the opinion stage. The CHMP issued a positive opinion on 2026-09-17, with Alexion Europe listed as the applicant. No EC decision is recorded as official yet.

The records do not state the therapeutic area or the approved indication, so this analysis cannot say which patients the product is for or what the labelled use is. The header's CHMP opinion date field is blank, but the milestone list does show the 2026-09-17 opinion. I treat the milestone entry as the more specific source.

Regulatory pathway and designations

In the US, the product went through a Biologics License Application (BLA), which is the standard route for a new biologic. The only designation recorded is 'New biologic'. The records show no orphan, breakthrough, priority review, fast track or accelerated approval status, and I do not infer any.

In the EU, a positive CHMP opinion is a scientific recommendation. It is not itself a marketing authorisation. The European Commission normally adopts a legally binding decision within about 67 days of the opinion, and that decision makes the product legally marketable across EU member states.

The records give an expected EC decision date of 2026-11-23. It is calculated as the CHMP opinion date plus 67 days, and the date arithmetic is consistent. It is flagged as an estimate and not an official date, so it should not be treated as a confirmed timeline. The records do not say whether the EU application is under standard or accelerated assessment, or whether any conditional or exceptional-circumstances route applies.

Safety and pharmacovigilance

The records contain no safety information. They do not cover boxed warnings, contraindications, adverse event profiles, a REMS, risk management plan content, or post-marketing commitments.

Safety assessment of this product therefore needs the FDA label and approval documents, and the EU CHMP assessment report and product information once they are published.

What to watch

The main near-term item is the European Commission decision. The records estimate it around 2026-11-23, and the official decision date should be checked against the Union Register of medicinal products.

Other items to check once the documents are available:

- The full FDA label and review documents, to confirm the indication, dosing, warnings and any postmarketing requirements.

- The EU product information and assessment report, to see whether the EU and US indications align.

- Any later regulatory activity in other regions. The records show only the US and EU entries.

AI-generated on 2026-11-17 from the official records on this page (model claude-sonnet-5-5). It can contain errors: check the sources.

Same substance in other markets

Follow Klygefa

Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.

Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.